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OBJECTIVE—Common genetic variants in GCK and TCF7L2
are associated with higher fasting glucose and type 2 diabetes in
nonpregnant populations. However, their associations with glu-
cose levels from oral glucose tolerance tests (OGTTs) in preg-
nancy have not been assessed in a large sample. We hypothesized
that these variants are associated with quantitative measures of
glycemia in pregnancy.
RESEARCH DESIGN AND METHODS—We analyzed the as-
sociations between variants rs1799884 (GCK) and rs7903146
(TCF7L2) and OGTT outcomes at 24–32 weeks’ gestation in
3,811 mothers of European (U.K. and Australia) and 1,706
mothers of Asian (Thailand) ancestry from the HAPO cohort. We
also tested associations with offspring birth anthropometrics.
RESULTS—The maternal GCK variant was associated with
higher fasting glucose in Europeans (P  0.001) and Thais (P 
0.0001), 1-h glucose in Europeans (P  0.001), and 2-h glucose in
Thais (P  0.005). It was also associated with higher European
offspring birth weight, fat mass, and skinfold thicknesses (P 
0.05). The TCF7L2 variant was associated with all three maternal
glucose outcomes (P  0.03, P  0.0001, and P  0.0001 for
fasting and 1-h and 2-h glucose, respectively) in the Europeans
but not in the Thais (P  0.05). In both populations, both variants
were associated with higher odds of gestational diabetes mellitus
according to the new International Association of Diabetes and
Pregnancy Study Groups recommendations (P  0.001–0.08).
CONCLUSIONS—Maternal GCK and TCF7L2 variants are as-
sociated with glucose levels known to carry an increased risk of
adverse pregnancy outcome in women without overt diabetes.
Further studies will be important to determine the variance in
maternal glucose explained by all known genetic variants.
Diabetes 59:2682–2689, 2010
M
aternal glycemia in pregnancy is associated
with adverse pregnancy outcomes including
birth weight 90th percentile, delivery by
cesarean section, neonatal hypoglycemia,
and fetal hyperinsulinemia (1). These associations occur
across the full range of maternal glucose levels below
those classiﬁed as overt diabetes.
In healthy, nondiabetic, nonpregnant populations, ap-
proximately one-third of the variation in fasting glucose is
genetic (2), and common genetic variants at multiple loci
are now robustly associated with fasting glucose (3–10)
and with type 2 diabetes and related glycemic traits
(11–18). Thus, genetic factors are likely to contribute to
variation in glucose levels in pregnancy. However, these
variants have not been examined extensively in large
studies of pregnant women.
Studies of birth weight in Europeans have provided indi-
rect evidence that two common genetic variants inﬂuence
maternal glycemia in pregnancy. The T-allele of the
rs1799884 variant in the GCK gene is associated with higher
fasting glucose in the general population (4) and with type 2
diabetes (10). Pregnant women who carry this allele give
birth to babies that are, on average, 32 g (95% CI 11–53)
heavier at birth (4). Similarly, each additional T-allele of
rs7903146 in the TCF7L2 gene—which is associated with
reduced -cell function, raised fasting glucose, and type 2
diabetes (10,13,19)—is also associated with a 30-g (95% CI
15–45) higher offspring birth weight when carried by the
mother (20). We hypothesize that these associations with
birth weight reﬂect higher levels of maternal glucose, which
result in greater fetal insulin secretion and a consequent
increase in fetal size at birth (21).
There is some evidence from small studies that the GCK
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in pregnancy or gestational diabetes mellitus. The GCK
variant was associated with higher fasting glucose in 755
European pregnant women from the U.K. (22) and with
gestational diabetes mellitus in a Scandinavian sample
(23). Variation at the TCF7L2 locus was not associated
with fasting glucose in 921 European pregnant women (20)
but was associated with gestational diabetes mellitus in
Scandinavian (24,25), Korean (26), and Mexican-American
(27) samples.
The large sample size and detailed pregnancy and birth
phenotype data available in the Hyperglycemia and Ad-
verse Pregnancy Outcome (HAPO) study provide a unique
opportunity to investigate more thoroughly the associa-
tions of the GCK and TCF7L2 variants with maternal
glycemia, as measured in an oral glucose tolerance test
(OGTT), during pregnancy as well as fetal size at birth and
body composition. We used OGTT results from 5,517
pregnant women of European and South East Asian an-
cestry to assess associations both with quantitative mea-
sures of maternal glucose and with the new International
Association of Diabetes and Pregnancy Study Groups
(IADPSG) recommendations for the diagnosis of gesta-
tional diabetes mellitus (28).
RESEARCH DESIGN AND METHODS
We studied 3,811 pregnant women of European ancestry (Manchester and
Belfast, U.K., and Newcastle and Brisbane, Australia) and 1,706 pregnant
women of South East Asian ancestry (Bangkok, Thailand). The protocol was
approved by the institutional review board at each ﬁeld center, and all
participants gave written, informed consent.
Maternal phenotypes and exclusion criteria. The HAPO study methods
have previously been described in detail (1,29,30). Brieﬂy, eligible women (30)
underwent a 75-g OGTT at 24–32 weeks’ gestation (as close to 28 weeks as
possible). Fasting, 1-h, and 2-h glucose levels were measured. Height, weight,
and blood pressure were also measured using standardized procedures and
calibrated equipment. A sample for random plasma glucose was collected at
34–37 weeks’ gestation as a safety measure to identify cases with hypergly-
cemia above a predeﬁned threshold. Gestational age was determined as
previously described (30). Demographic and lifestyle characteristics, age, and
parity were collected via questionnaire. Race/ethnicity was self-identiﬁed.
Participants, caregivers, and HAPO study staff (except laboratory person-
nel) remained blinded to glucose values unless fasting plasma glucose was
5.8 mmol/l, 2-h OGTT plasma glucose was 11.1 mmol/l, random plasma
glucose was 8.9 mmol/l, or any plasma glucose value was 2.5 mmol/l.
Although unblinded participants were excluded from the original HAPO study
of pregnancy outcome (1), we did not exclude them from maternal glucose
analyses in the current study because there was no intervention to alter
maternal glucose levels before the OGTT.
Neonatal phenotypes. Cord blood samples for DNA, plasma glucose, and
serum C-peptide were collected from the offspring at delivery. Neonatal anthro-
pometric data were collected within 72 h of delivery. These have been described
in detail previously (31). In the current study, we analyzed weight, length, head
circumference, triceps, and ﬂank and subscapular skinfold thicknesses. Birth
weight, length, and head circumference were available from medical records in
addition to the measurements taken by HAPO study personnel. To maximize
sample size, we used the medical record birth weight because it was more widely
available and highly correlated with the HAPO-measured birth weight (r  0.98).
We used the HAPO study measures for length and head circumference and added
medical record values when these were unavailable. Fat mass at birth (grams)
was derived using the following formula (32):
1,000  (0.39055  BW/1,000  0.0453  FLS  0.03237  BL  0.54657)
(1)
where BW is birth weight in grams, FLS is ﬂank skinfold thickness in
millimeters, and BL is birth length in centimeters (all measured by HAPO
study personnel). From this, percent body fat was derived as follows: 100 
fat mass/birth weight.
Genotyping. We selected the rs1799884 (GCK) and rs7903146 (TCF7L2)
single nucleotide polymorphisms (SNPs) for association analysis. As well as
being robustly associated with higher fasting glucose and type 2 diabetes in
Europeans (4,10,19), these SNPs, or perfectly correlated (r
2  1) proxies,
show similar associations in East Asian and South Asian populations (33–37).
We therefore carried out our primary analyses using only these SNPs.
However, we also selected TCF7L2 rs290487 and rs11196218 for analysis in
our Thai samples because they have shown independent evidence of associ-
ation with type 2 diabetes in East Asians (r
2  0.1 with rs7903146 and r
2  0.01
with each other in the HapMap Han Chinese from Beijing and Japanese from
Tokyo reference samples) (35,38–40) and are more common than rs7903146
in these samples, giving greater power to detect associations.
Genotyping was carried out as part of a larger candidate panel of 1,536 SNPs
using the Illumina Golden Gate platform in the Northwestern University Genom-
ics Core. We included DNA samples in our study that were successfully
genotyped for over 94% of SNPs. Call rates for the GCK and TCF7L2 SNPs
exceeded 99% in these samples, and there was not deviation from Hardy-
Weinberg equilibrium (P0.01 for the four SNPs in each of the ﬁve ﬁeld centers).
The frequency of the T-allele of GCK rs1799884 (associated with higher glucose
levels) ranged from 17.1 to 18.7% in the European samples and was 10.3% in the
Thai sample. The type 2 diabetes risk allele frequency of TCF7L2 rs7903146
ranged from 29.2 to 30.6% in the Europeans and was 4.7% in the Thai. The
rs290487 and rs11196218 risk allele frequencies (risk alleles deﬁned by previous
studies) (35,38–40) were 47.4 and 72.4%, respectively, in the Thai sample.
Statistical analyses: associations between maternal genotype and ma-
ternal glycemia. All analyses were carried out using Stata (version 10; Stata,
College Station, TX). We analyzed the association between each of the three
primary outcome measures (fasting plasma glucose, 1-h OGTT glucose, and
2-h OGTT glucose) and genotype using linear regression under an additive
genetic model. We included maternal age, BMI, and mean arterial pressure as
covariates in the model. We repeated the analysis including additional
covariates (BMI squared, gestational age at OGTT, parity, sex of the baby, and
maternal height) to check that they did not change the results. We analyzed
the European and Thai samples separately and included ﬁeld center as a
covariate in all analyses of Europeans.
We also sought to investigate the association of each SNP with maternal
glucose levels that carry a substantially higher risk of adverse pregnancy
outcome. We created a high glucose variable with a value of 1 if the participant
had one or more high values in the OGTT (fasting plasma glucose 5.1
mmol/l, 1-h glucose 10.0 mmol/l, or 2-h glucose 8.5 mmol/l) and a value of
0 if the glucose was below these thresholds. The high glucose threshold
corresponds to an odds ratio (OR) of 1.75, relative to the mean glucose level,
averaged across three outcomes in the HAPO study: offspring birth weight
90th percentile, cord C-peptide 90th percentile, offspring percent body fat
90th percentile, and is the IADPSG-recommended threshold for gestational
diabetes mellitus (28). We analyzed the association between each SNP and the
odds of high glucose using logistic regression (log-additive genetic model),
adjusting for ﬁeld center (European ancestry samples only) maternal age,
BMI, and mean arterial pressure. Using all 5,515 study subjects with both GCK
and TCF7L2 genotype available (and adjusting for ﬁeld center), we then
analyzed the association between the odds of high glucose and the combined
number of T-alleles at both loci (0, 1, 2, and 3 or 4), with the same covariates
as before. We combined individuals with three or four T-alleles into one group
because of low numbers in the ﬁnal category. To test for deviation from a
multiplicative trend across the four groups, we compared the results with a
full model (including the allele score as indicator variables) using a likelihood
ratio test.
To guard against possible population stratiﬁcation, we generated principal
components of ancestry using smartpca from the Eigensoft software package
(41) based on 141 ancestry informative markers that were genotyped in the
same panel of 1,536 SNPs as the GCK and TCF7L2 SNPs. We repeated our
analyses including the ﬁrst two principal components as covariates.
Associations between maternal genotype and neonatal anthropometric
traits. We analyzed the association between each neonatal outcome and
maternal genotype using linear regression (additive genetic model). We
performed the analysis twice: 1) a minimally adjusted model with ﬁeld center
(European ancestry only), sex of the baby, and gestational age at delivery as
covariates and 2) a fully adjusted model including maternal age at OGTT,
maternal BMI at OGTT, maternal BMI at OGTT squared, parity, maternal
smoking (yes/no), mean arterial pressure, and maternal height as additional
covariates. The ﬁrst analysis was performed to enable comparison with
previously published studies (4,20,22), and the second was performed for
comparison with the ﬁrst to verify that the additional covariates did not
change the results. All analyses of neonatal outcomes excluded babies born
preterm (before 37 full weeks of gestation) and pregnancies in which
caregivers were unblinded to maternal glucose levels.
We performed inverse variance meta-analysis (ﬁxed effects) of the associ-
ation between each SNP and birth weight to combine the HAPO study data
with data from previously published studies (4,20,22). Within each study
sample, the association between genotype and birth weight was analyzed
using linear regression under an additive genetic model, with sex and
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METAN module developed for Stata (42). Heterogeneity between studies was
estimated using Cochran’s Q test and the I
2 statistic (43). We also used
Cochran’sQtest to assess evidence of heterogeneity between the analyses of
maternal glucose outcomes in the European and Thai samples.
Associations between fetal genotype and birth weight. We analyzed the
association between birth weight and fetal genotype using linear regression
(additive model), adjusting for ﬁeld center (European ancestry only), sex, and
gestational age and again excluding preterm births and unblinded pregnancies.
Since maternal and fetal genotypes are correlated, we then repeated the analysis
stratifying by maternal genotype and tested for evidence of a fetal genotype–birth
weight association within each stratum. To address whether fetal genotype alters
the impact of maternal glucose levels on offspring birth weight, fat mass, or
skinfold thickness, we additionally tested for evidence of interaction between
fetal genotype and maternal glucose using a likelihood ratio test.
Power calculations. Our sample of 3,811 Europeans gave us 80% power to
detect per-allele differences in an outcome of 0.09 SD and 0.07 SD for the GCK
and TCF7L2 SNPs, respectively, at P  0.05. Due to the lower sample size and
allele frequencies in the Thai sample, power to detect these associations was
reduced (35 and 14%, respectively). Power calculations were performed using
Quanto, version 1.2 (44).
Comparing the discriminatory impact of maternal genotype with mea-
sured glucose on birth weight and neonatal adiposity. To address
whether maternal GCK and TCF7L2 genotypes improve prediction of birth
weight or neonatal adiposity in the presence of different combinations of other
known variables, we used logistic regression to model the odds of birth
weight, skinfold sum, and percent body fat 90th percentile against various
explanatory variables, including both maternal GCK and TCF7L2 genotypes
(included as indicator variables). We constructed receiver operator charac-
teristic (ROC) curves and calculated the area under the curve (AUC) to
estimate the discriminatory power of the model. The AUCs were compared for
various models using a 
2 test. For this analysis, we combined all of the study
subjects and adjusted for study center.
RESULTS
Associations between maternal genotype and mater-
nal glycemia. Basic characteristics of the study partici-
pants are presented in Table 1. The associations between
continuous measures of maternal glucose, as determined
during an OGTT, and the GCK and TCF7L2 variants are
presented in Table 2 and Table 3, respectively. Summary
data from each of the ﬁeld centers with European
ancestry women are presented in supplementary Tables
1 and 2, available in an online appendix (http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0177/DC1).
We observed associations between the GCK rs1799884
variant and fasting glucose in both the European (0.03
mmol/l higher per T-allele [95% CI 0.01–0.05]; P  0.001)
TABLE 1
Basic characteristics of study participants
Belfast,
U.K.
Manchester,
U.K.
Brisbane,
Australia
Newcastle,
Australia
Bangkok,
Thailand
Pregnant women (n)* 1,284 1,085 959 483 1,706
Gestational age at which OGTT was performed (weeks) 29.0 	 1.2 28.4 	 1.0 28.1 	 1.2 28.1 	 1.5 28.1 	 1.7
Age at OGTT (years) 29.8 	 5.5 30.8 	 5.6 29.2 	 5.3 29.5 	 5.5 27.9 	 5.5
BMI at OGTT (kg/m
2) 28.4 	 4.9 29.0 	 5.5 29.0 	 5.7 29.7 	 6.0 25.6 	 3.6
Mean arterial pressure at OGTT (mmHg) 83.6 	 7.9 83.5 	 8.0 83.8 	 7.7 82.9 	 8.1 80.1 	 7.8
FPG (mmol/l) 4.63 	 0.37 4.61 	 0.40 4.43 	 0.35 4.54 	 0.41 4.44 	 0.37
1-h plasma glucose (mmol/l) 7.50 	 1.70 7.46 	 1.80 7.40 	 1.51 7.33 	 1.66 8.27 	 1.75
2-h plasma glucose (mmol/l) 6.08 	 1.23 5.99 	 1.35 6.25 	 1.20 6.21 	 1.33 6.66 	 1.40
Offspring birth weight in g† 3,526 	 489 3,511 	 498 3,552 	 466 3,585 	 466 3,142 	 399
Gestational age at delivery (weeks)† 40.1 	 1.1 40.0 	 1.3 40.0 	 1.2 40.1 	 1.2 39.4 	 1.2
Male offspring (%)† 50.6 52.1 51.1 51.2 48.7
Maternal smoking during pregnancy (%)† 23.7 19.2 13.2 15.5 0.6
Primiparous births (%)† 50.2 47.8 55.8 46.1 53.3
Data are means 	 SD unless otherwise indicated. *Number of women with fasting glucose, GCK rs1779984 genotype, age, BMI, and mean
arterial pressure available. The numbers with TCF7L2 rs7903146 genotype were very similar. †Excluding births before 37 completed weeks
of gestation and pregnancies in which caregivers were not blinded to maternal glucose levels. FPG, fasting plasma glucose.
TABLE 2
Association between maternal GCK rs1799884 genotype and maternal glucose levels in pregnancy
Total N
Mean 	 SE plasma glucose level by GCK
rs1799884 genotype Effect size 	 SE per
T-allele (mmol/l)*† P† CC CT TT
FPG (mmol/l)
European 3,811 4.55 	 0.01 4.59 	 0.01 4.63 	 0.03 0.03 	 0.01 0.001
Thai 1,706 4.42 	 0.01 4.51 	 0.02 4.52 	 0.08 0.08 	 0.02 0.0001
1-h plasma glucose (mmol/l)
European 3,811 7.39 	 0.03 7.54 	 0.05 7.69 	 0.15 0.15 	 0.05 0.001
Thai 1,706 8.25 	 0.05 8.35 	 0.09 8.54 	 0.37 0.11 	 0.09 0.24
2-h plasma glucose (mmol/l)
European 3,811 6.11 	 0.02 6.12 	 0.04 6.18 	 0.11 0.02 	 0.04 0.56
Thai 1,706 6.61 	 0.04 6.85 	 0.08 6.81 	 0.30 0.21 	 0.07 0.005
The European plasma glucose levels by genotype are the mean values across all four ﬁeld centers. These are presented separately in
supplementary Table 1. *The T-allele of GCK rs1799884 is associated with raised fasting glucose in nondiabetic, nonpregnant populations.
The T-allele frequency ranged from 17.1 to 18.7% in the European ancestry samples and was 10.3% in the Thai samples. †The effect sizes and
P values are from linear regression of maternal glucose level against genotype (coded 0, 1, or 2 T-alleles), with ﬁeld center (European ancestry
only), age, BMI, and mean arterial pressure as covariates. Age, BMI, and mean arterial pressure were measured at a median of 28–29 weeks’
gestation, depending on the ﬁeld center. Mean 	 SE values are adjusted for these three covariates. FPG, fasting plasma glucose.
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0.12]; P  0.0001). We also observed an association with
1-h glucose in the Europeans (P  0.001) but not in the
Thais (P  0.24). However, the estimated differences were
similar (per T-allele increase 0.15 mmol/l [0.06–0.25] in the
Europeans and 0.11 mmol/l [0.07 to 0.29] in the Thais).
There was evidence of association with 2-h glucose in the
Thai sample (0.21 mmol/l higher per T-allele [95% CI
0.06–0.35]; P  0.005), but not in the Europeans (0.02
mmol/l per T-allele [0.05–0.09]; P  0.56). There was
evidence of heterogeneity between the European and Thai
samples for the fasting (P  0.03) and 2-h (P  0.02)
glucose measures but not the 1-h measure (P  0.70).
When we repeated these analyses including additional
covariates, we observed similar results (supplementary
Table 3).
In the European samples, we observed associations
between the TCF7L2 rs7903146 variant and both 1-h (0.16
mmol/l higher per T-allele [95% CI 0.08–0.24]; P  0.0001)
and 2-h (0.13 mmol/l higher per T-allele [0.07–0.19]; P 
0.0001) glucose levels. There was also some evidence for
association with fasting glucose (0.02 mmol/l higher per
T-allele [0.002–0.03]; P  0.03). We observed no evidence
for association at P  0.05 between the TCF7L2 variant
and the maternal glucose measures in the Thai samples,
reﬂecting either no association in this population or re-
duced power due to the lower minor allele frequency. The
estimated differences were similar to those in the Europe-
ans (all heterogeneity P values 0.6). When we repeated
these analyses including additional covariates, we ob-
served similar results (supplementary Table 4). There
were also no associations between any of the maternal
glucose outcomes and the TCF7L2 rs290487 or rs11196218
SNPs in the Thai sample (P  0.05; data not shown).
Consistent with the results for continuous glucose mea-
sures, we observed associations between both the GCK
and TCF7L2 variant and the odds of high glucose, deﬁned
by the IADPSG (28) as having one or more of the follow-
ing: fasting plasma glucose 5.1 mmol/l, 1-h glucose 10.0
mmol/l, and 2-h glucose 8.5 mmol/l (Table 4). In the
Europeans, 26% of women with the GCK rs1799884 TT
genotype had high glucose, compared with 15% with the
CC genotype, and the per-allele OR was 1.29 (95% CI
1.09–1.50). The corresponding OR in the Thai sample was
1.42 (1.06–1.77). For TCF7L2 rs7903146, 20% of women of
European ancestry with the TT genotype had high glucose,
compared with 16% with the CC genotype. The per-allele
ORs were 1.15 (1.00–1.31) in the Europeans and 1.39
(0.88–1.90) in the Thais. Analysis of the complete dataset,
combining information from both GCK and TCF7L2,
showed strong evidence for a trend to increased odds of
high glucose with an increasing number of T-alleles (OR
1.25 [95% CI 1.14–1.37]; P  0.00001) (supplementary Fig.
TABLE 3
Association between maternal TCF7L2 rs7903146 genotype and maternal glucose levels in pregnancy
Total N
Mean 	 SE plasma glucose level by
TCF7L2 rs7903146 genotype Effect size 	 SE per
T-allele (mmol/l)*† P† CC CT TT
FPG (mmol/l)
European 3,811 4.56 	 0.01 4.55 	 0.01 4.63 	 0.02 0.02 	 0.01 0.03
Thai 1,706 4.44 	 0.01 4.45 	 0.03 4.44 	 0.21 0.01 	 0.03 0.66
1-h plasma glucose (mmol/l)
European 3,811 7.34 	 0.04 7.51 	 0.04 7.65 	 0.08 0.16 	 0.04 0.0001
Thai 1,706 8.25 	 0.04 8.53 	 0.13 7.39 	 0.96 0.23 	 0.14 0.09
2-h plasma glucose (mmol/l)
European 3,811 6.04 	 0.03 6.18 	 0.03 6.27 	 0.06 0.13 	 0.03 0.0001
Thai 1,706 6.64 	 0.03 6.86 	 0.11 5.81 	 0.77 0.17 	 0.11 0.11
The European plasma glucose levels by genotype are the mean values across all four ﬁeld centers. These are presented separately in
supplementary Table 2. *The T-allele of TCF7L2 rs7903146 is associated with an increased risk of type 2 diabetes. The T-allele frequency
ranged from 29.2 to 30.6% in the European ancestry samples and was 4.7% in the Thai samples. †The effect sizes and P values are from linear
regression of maternal glucose level against genotype (coded 0, 1, or 2 T-alleles), with ﬁeld center (European ancestry only), age, BMI, and
mean arterial pressure as covariates. Age, BMI, and mean arterial pressure were measured at a median of 28–29 weeks’ gestation, depending
on the ﬁeld center. Mean 	 SE values by genotype are adjusted for these three covariates. FPG, fasting plasma glucose.
TABLE 4
Association between GCK or TCF7L2 genotype and high* mater-
nal glucose levels
Ancestry and
genotype
No. of
women with
high/normal
glucose
(% high)
Per T-allele OR
(95% CI) for
high glucose† P†
GCK rs1799884
European 1.29 (1.09–1.50) 0.001
CC 388/2,575 (15.1)
CT 194/1,114 (17.4)
TT 32/122 (26.2)
Thai 1.42 (1.06–1.77) 0.007
CC 288/1,375 (20.9)
CT 91/311 (29.3)
TT 5/20 (25.0)
TCF7L2 rs7903146
European 1.15 (1.00–1.31) 0.04
CC 293/1,884 (15.6)
CT 246/1,557 (15.8)
TT 75/370 (20.3)
Thai 1.39 (0.88–1.90) 0.08
CC 338/1,549 (21.8)
CT/TT‡ 46/157 (29.3)
*Deﬁned as fasting glucose 5.1 mmol/l or 1-h glucose 10.0 mmol/l
or 2-h glucose 8.5 mmol/l. †ORs and P values are from logistic
regression of high glucose status (1 or 0) against genotype (coded 0,
1, or 2 T-alleles), with ﬁeld center (European ancestry only), age,
BMI, and mean arterial pressure as covariates. Age, BMI, and mean
arterial pressure were measured at a median of 28–29 weeks’
gestation, depending on the ﬁeld center. ‡Categories are combined
because of the small number of TT homozygotes (n  3).
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tive model (P  0.28).
Inclusion of the ﬁrst two ancestry principal components
as covariates did not change the associations between the
GCK and TCF7L2 variant and maternal glucose outcomes
(data not shown). A sensitivity analysis including only
participants whose caregivers remained blinded to glucose
levels gave very similar results for all associations.
Associations between maternal genotype and neona-
tal anthropometric traits. Meta-analysis of the associa-
tions between the maternal GCK and TCF7L2 variants and
offspring birth weight, using both Thai and European study
samples, showed that those in the HAPO study were
consistent in size and direction with previously published
studies of Europeans (heterogeneity P values 0.05; I
2 
20%) (Fig. 1). The overall P values for association with
birth weight were P  0.0001 for maternal GCK rs1799884
(n  12,643) and P  0.001 for maternal TCF7L2
rs7903146 (n  13,406).
We analyzed the associations between the maternal
GCK and TCF7L2 variants and various neonatal traits
(supplementary Tables 5 and 6). We did not observe an
association with cord C-peptide at either locus (P  0.05).
After Bonferroni adjustment for 10 tests, there was no
association at P  0.05 with neonatal anthropometric
traits at either locus. However, in the Europeans, the GCK
rs1799884 effect size estimates for all traits were in the
direction expected, given the association with maternal
glucose, and the unadjusted P values for association with
birth weight, fat mass, percent body fat, and skinfold
thickness were all 0.05.
Associations between fetal genotype and birth
weight. We observed no overall association between birth
weight and the fetal genotype at either locus (P  0.05;
data not shown). To address the correlation between
maternal and fetal genotype, we stratiﬁed by maternal
genotype, but there was no evidence of association (P 
0.05) after multiple testing correction (supplementary Fig.
2). We observed no evidence of interaction between fetal
genotype and maternal glucose levels on offspring birth
weight, fat mass, or skinfold thickness (P  0.05; data not
shown).
Using ROC curves to evaluate the impact of maternal
genotype versus maternal glucose on birth weight
and neonatal adiposity. We next addressed 1) whether
maternal GCK and TCF7L2 genotypes improve prediction
of birth weight or neonatal adiposity when maternal
fasting glucose is not known and 2) whether knowledge of
maternal genotypes improves prediction of birth weight or
neonatal adiposity when maternal fasting glucose is
known but maternal 1- and 2-h glucose values are not
known. When maternal fasting glucose was added to a
model containing various covariates, the observed area
under the ROC curves for birth weight, skinfold sum, and
percent body fat 90th percentile increased (P  0.05). In
contrast, the addition of maternal genotype at GCK and
TCF7L2 did not result in increased discriminatory ability
(P  0.05). Similarly, genotype did not improve the AUCs
when considered alongside fasting glucose, whereas mea-
sured 1- and 2-h glucose values did result in improvement
(P0.05; supplementary Table 7).
DISCUSSION
In our study of 5,517 women of European and Thai
ancestry, we have shown for the ﬁrst time associations
between variants at the GCK and TCF7L2 loci and contin-
uous OGTT measures of maternal glucose in pregnant
women without overt diabetes. An additional new ﬁnding
in this study is association of these variants with gesta-
tional diabetes mellitus, as deﬁned by the new IADPSG
consensus recommendation (28), itself associated with
higher risk of adverse birth outcomes.
The GCK rs1799884 variant was associated with fasting
glucose in both of our study populations. The association
in the Thai sample was similar to associations previously
observed in nonpregnant East Asian subjects (37), while
the estimated fasting glucose difference per allele in the
Europeans was smaller than previously observed (P 
0.02) (7). We observed some evidence of heterogeneity,
with the Thai sample showing a tendency to larger per-
allele differences than the European ancestry sample (P 
0.03). This is consistent with previous observations from
East Asian, but not South Asian, versus European analyses
(36,37). Changes in glucokinase activity or content in
pancreatic -cells are known to impact primarily on
fasting glucose levels (45). However, the rate of -cell
glucose metabolism—and, hence, insulin secretion—is
controlled by glucokinase across the full range of glucose
levels (46,47), and mutations of the glucokinase gene
Overall 
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HAPO_THAI 
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30 (3, 57) 
65 (10, 121) 
30 (15, 44) 
23 (-22, 68) 
27 (7, 46) 
0  -30  0  30  60  90  120 150 
Change in birth weight (g) per 
GCK rs1799884 T-allele (95%CI)  A
Overall 
NCCGP 
HAPO_EUR 
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HAPO_THAI 
ALSPAC 
23 (11, 35) 
2 (-37, 41) 
8 (-15, 30) 
30 (-13, 73) 
29 (-37, 95) 
35 (17, 53) 
0  -30  0  30  60  90  120 
Change in birth weight (g) per 
TCF7L2 rs7903146 T-allele (95%CI)  B
FIG. 1. Meta-analysis of the association between offspring birth weight
and maternal GCK rs1799884 genotype (overall P < 0.0001) (A)o r
maternal TCF7L2 rs7903146 genotype (overall P < 0.001) (B)i nt h e
HAPO study and previously published studies (4,20,22). Analyses were
adjusted for sex and gestational age. ALSPAC, Avon Longitudinal
Study of Parents and Children; EFSOCH, Exeter Family Study of
Childhood Health; NCCGP, North Cumbria Community Genetics
Project.
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tolerance test compared with non–mutation-carrying fam-
ily members (48). In keeping with this, GCK rs1799884 was
associated with higher 1-h glucose levels in the European
population in our study and higher 2-h glucose levels in the
Thais. Association of GCK rs1799884 with 2-h glucose was
demonstrated previously in a European study of nonpreg-
nant individuals (49).
The TCF7L2 rs7903146 variant showed associations at
P  0.05 with all measures of maternal glucose, but these
were largest for 1- and 2-h glucose—in keeping with the
known association of this locus with glucose-stimulated
insulin secretion and incretin signaling in the islet (13).
Despite the lower minor allele frequency in the Thai
sample, the glucose differences per allele for all three
measures were similar to those observed in the
Europeans.
Previous studies of both GCK and TCF7L2 have
shown associations with gestational diabetes mellitus
(23,24,26,27). In keeping with these, we have shown asso-
ciations with the new consensus deﬁnition of gestational
diabetes mellitus (28) in both the European and Thai
samples. We observed strong evidence for a trend to
higher odds of high glucose with increasing numbers of
T-alleles at GCK and TCF7L2 (P  0.00001) but found no
evidence for statistical interaction between these loci (P 
0.2). It is important that we now assess the impact of all
conﬁrmed fasting glucose and type 2 diabetes susceptibil-
ity loci on maternal glycemia because we are likely to
identify extreme groups within the population who are at
greatly increased genetic risk of high glucose levels in
pregnancy. Due to the adverse impact of glucose levels per
se on offspring phenotype, genetic variants that are only
associated with steady-state glucose regulation may be
associated with potentially harmful outcomes in preg-
nancy even if they are not associated with disease risk in
nonpregnant adults.
It is important to understand the contribution of these
variants to nenonatal outcomes. The associations that we
observed between the maternal risk allele at both loci and
higher offspring birth weight were similar to those previ-
ously published (4,20). Our ﬁnding that the GCK variant
showed adiposity associations consistent with the contin-
uous relationship between glucose and neonatal adiposity
(31) is a novel observation that extends the previously
demonstrated association of this variant with birth weight.
Larger studies or meta-analyses will be necessary to
provide enough statistical power with which to investigate
thoroughly the associations between maternal genotype
and neonatal anthropometrics. Consistent with previous
studies (4,20,22), we observed no association between
birth weight and fetal genotype, suggesting that, unlike
rare fetal mutations in GCK (50), the common variants at
GCK and TCF7L2 do not inﬂuence fetal growth directly.
Measurement of maternal glucose can help identify
women without overt diabetes who have a higher risk of
neonatal adiposity 90th percentile (31). We hypothesized
that maternal GCK and TCF7L2 genotypes might add
useful information for predicting neonatal birth weight,
skinfold sum, and percent body fat 90th percentile when
maternal glucose is not known. Using ROC curves, we
found that maternal genotypes did not improve the dis-
criminatory ability of the models (P  0.05). This may
reﬂect that genotypes at these variants explain only a
small proportion (1%) of variance in maternal glucose
levels. However, a total of 16 genetic variants are now
known to explain 3–4% of the variation in fasting glucose
in Europeans (10). It will therefore be important to repeat
these analyses with all known variants.
To conclude, variants at the GCK and TCF7L2 loci,
which predispose to higher fasting glucose and type 2
diabetes in the general population, are associated with 1)
higher glucose levels from OGTTs in pregnant women who
do not have overt diabetes and 2) gestational diabetes
mellitus under the new consensus deﬁnition (28). Further
well-powered studies will be important to assess fully the
contribution of known genetic variants to maternal glyce-
mia in pregnancy, pregnancy outcomes, and neonatal
phenotypes.
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